Navigation Links
BF-1T40 Fiber Bronchoscope

ProductsBF-1T40 Fiber Bronchoscope
Company Olympus America Medical
Item BF-1T40 Fiber Bronchoscope
Features 
  • Large 2.8mm channel
  • Wide 120-degree field of view provides for expanded viewing
  • Tip bending range of 180 UP and 130 DOWN
  • New suction and biopsy valves allow BAL testing to be performed more efficiently
  • Accessories are disposable or autoclavable for easier cleaning
  • Compatible with electrosurgical accessories BF-1T40 Bronchofiberscope
Description The BF-1T40 has been designed with a large 2.8mm instrument channel for superb versatility in therapeutic applications. This permits the selection of a wide variety of accessories including those for electrosurgical procedures. In addition, this model features excellent optics with a wide field of view and a bright, high-resolution image. It also provides improved operability, increased BAL efficiency and enhanced ability to clean via a number of easy-to-use features and a new ergonomic design.
Info Olympus America Medical
Customer Service: (800) 848-9024
Web site: http://www.olympusamerica.com

Related medicine products :

1. Micro-Mini Fiber Optic Light - HLT150
2. Micro-Mini Fiber Optic Light - HLT200
3. Micro-Mini Fiber Optic Light - Source 100
4. Nagashima Rigid Fiber Optic Antroscope SFA-I
5. Nagashima Rigid Fiber Optic Antroscope SFA-II-W
6. Nagashima Rigid Fiber Optic Antroscope SFA-II
7. Coaxial Fiberoptic Headlights
8. Fiberoptic Lightweight Coaxial Rotary Headlight
9. Neuroview Rigid Body Fiberoptic Neuroendoscopes
10. Fiberoptic CIS Set
11. Disposable Laser Fiber (For 12 Watt Laser)
Breaking Medicine Technology:GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4New Executive Leadership and CEO Announced for BiPar Sciences 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 1Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 2Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 3Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost 12946 4Research shows that invisible hand guides evolution of cooperative turn taking 9182 1Research shows that invisible hand guides evolution of cooperative turn taking 9182 2Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 4702 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 4702 2